Yazar "Şimşek, Hakkı" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe COVID-19 ve kardiyovasküler hastalıklar(Dicle Üniversitesi Tıp Fakültesi, 2021) Demir, Muhammed; Özbek, Mehmet; Şimşek, HakkıKoronavirüs hastalığı 2019 (COVID-19), şiddetli akut solunum sendromu koronavirüs 2 (Sars-CoV-2)’nin yol açtığı bir viral enfeksiyondur. İlk kez Aralık 2019'da Çin'in Wuhan şehrinde tespit edildi ve küresel bir sağlık krizine dönüştü. Bu derlemede COVID-19 ile kardiyovasküler hastalıkların ilişkisi, fizyopatolojisi, klinik seyri, prognozu ve tedavi yönetimi ele alındı. Pubmed, Google Scholar, Scopus, Science Direct veri tabanlarından COVID-19 ve kardiyovasküler hastalıklarla ilişkili bilimsel araştırmalar derlendi. Hastalığın epidemiyolojisi, fizyopatolojisi, kardiyovasküler hastalıklarla ilişkisi, klinik seyri ele alındı. COVID-19’un aritmilerden, kalp yetmezliğine kadar geniş spektrumda kalp hastalıklarıyla yakından ilişkili olduğu, aynı zamanda var olan kardiyovasküler hastalıkların COVID-19’un morbidite ve mortalitesini belirgin derecede artırdığı izlendi.Öğe An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER*-2 study design(Türk Kardiyoloji Derneği, 2015) Ertaş, Faruk; Kaya, Hasan; Yıldız, Abdulkadir; Davutoğlu, Vedat; Kiriş, Abdulkadir; Dinç, Lale; Kafes, Habibe; Avcı, Anıl; Çalapkorur, Bekir; Ertaş, Gökhan; Gül, Mehmet; Ay, Nuray Kahraman; Bulur, Serkan; Durukan, Mine; Eren, Murat; İlhan, İbrahim; Küçük, Murathan; Özpelit, Ebru; Şimşek, Hakkı; Uçar, F. Mehmet; Yıldız, Ahmet; Şahin, Yıldıray; Ayhan, Erkan; Çağlayan, Emre; Güngör, Hasan; Özyurtlu, Ferhat; Şen, Nihat; Vatan, Bülent; Vatansever, Fahriye; Kobat, Mehmet Ali; Temiz, Ahmet; Taylan, Gökay; Dönmez, İbrahim; Erkuş, M. Emre; Söylemez, Selami; Zengin, Halit; Gündüz, Mahmut; Tuncez, Abdullah; Karavelioğlu, Yusuf; Gökdeniz, Tayyar; Koza, Yavuzer; Aktop, Ziyaeddin; Katlandur, Hüseyin; Özer, Pelin Karaca; Yüksel, Murat; Acet, Halit; Çil, Habib; Alan, Sait; Toprak, NizamettinObjectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients. Study design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization). Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016. Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials.gov number, NCT02354456.).Öğe Global longitudinal strain score predicts all cause death in patients with chronic total occlusion with preserved ejection fraction(Verduci Editore s.r.l, 2022) Özbek, Mehmet; Bilik, Mehmet Zihni; Demir, Muhammed; Arık, Baran; Şimşek, Hakkı; Ertaş, Faruk; Toprak, NizamettinOBJECTIVE: Change in LVEF is one of the most important indicators of prognosis in CTO cases. Studies in patients with CTO have shown improvement in LVEF approximately at 3 and 6 months after successful PCI. It has been shown that LV global longitudinal strain (GLS) starts to improve even 1 day after CTOPCI. We aimed at investigating the effect of subclinical echocardiographic involvement on allcause mortality in the group with CTO and preserved ejection fraction by evaluating the LV GLS score. PATIENTS AND METHODS: Patients with LVEF ≥ 50% were considered to have preserved ejection fraction and were included in the study. The endpoint of the study was all-cause death. For this retrospective study, 1,171 patients with coronary angiography who had had CTO in any of their vessels were screened. RESULTS: A total of 86 consecutive patients were reviewed in the study. The optimum GLS score cut-off value (≥ 14.18) for predicting mortality was determined using receiver operating characteristic (ROC) curve analysis (AUC: 0.897, sensitivity 87.5%, specificity 81.5% p<0.001). At a mean follow-up of 49 months, a significant difference was found between the two groups in all-cause mortality determined by the GLS score [2 (3.4%) vs. 14 (51.9%), p<0.001]. A significant difference in mortality was observed between the group with a low GLS score and the group with a high GLS score, according to Kaplan-Meier analysis. The effect of GLS score in predicting all-cause mortality was demonstrated in multivariate cox regression analysis (Low GLS score; OR: 6.36 95%CI (1.039-39.013), p=0.045). Cox regression multivariate analysis and the effect of GLS score in predicting mortality were observed [Low GLS score; OR: 6.368 95%CI (1.039-39.013), p=0.045]. CONCLUSIONS: As a predictor, GLS may be a valuable marker of cardiac subclinical dysfunction for all caused mortality in CTO patients.Öğe Prognostic significance of monocyte to high-density lipoprotein ratio in patients with chronic coronary artery occlusion(Dicle Üniversitesi Tıp Fakültesi, 2022) Demir, Muhammed; Özbek, Mehmet; Aktan, Adem; Güzel, Tuncay; Aslan, Burhan; Şimşek, HakkıObjective: Monocyte to high-density lipoprotein ratio (MHR) is a biomarker of inflammatory response. In this study, we investigated the relationship between MHR and mortality in patients with chronic coronary artery occlusion (CTO). Method: Retrospective observational study including 493 patients over a follow up period of 73 months. Blood samples were taken before cardiac catheterization for coronary angiography. Results: Median follow-up was 48 months(26-73) . Patients were seperated into two groups: (I) MHR <17.68 (n=278, 95 females) and (II) MHR ≥17.68 (n=215, 45 females). Mortality was considerably higher in MHR II than in MHR I (n=70 vs. n=43; p<0,001). MHR was an independent predictor of mortality (OR: 1.089, 95% [CI]: 1.055-1.124, p<0,001). Lower survival rates were found in MHR II on Kaplan-Meier analyses when compared to that of MHR I (75.223±2.670 vs. 89.220±2.102, p<0,001). Conclusions: As a simple, easy applicable and universal marker, MHR may be a parameter that predicts mortality risk and survival time in CTO patients.
